-
Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C
China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its Category 1 chemical drug, MBT-1608. The drug is targeted for the treatment of hepatitis C virus (HCV) and will…
